Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Quantifying Siderophores and Pyochelin for Infection Control
Published on: March 15, 2024
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W Nichols1, Gregory G Stone2, Paul Newell3
1AstraZeneca, Waltham, Massachusetts, USA wrightnichols1@gmail.com.
Abstract:
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.
Related Concept Videos
Magnetic Susceptibility and Permeability
When diamagnetic materials are placed under an external magnetic field, the moments opposite to the field are induced. Hence, the susceptibility for diamagnets has a minimal negative value of 10-5–10-6. Since...
Susceptibility, Permittivity and Dielectric Constant
Bioremediation
Social Proof
RNA Stability
Overview of DNA Repair
Chemically...

